- Home
- / Enanta Pharmaceuticals
Enanta Pharmaceuticals
Stock Price
$11.5
2024-10-29
Market Capitalization
$243.7 M
2024-10-29
Revenue
$65.3 M
FY, 2025
Enanta Pharmaceuticals Summary
Company Summary
- Overview
- Enanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule drugs for virology and immunology. It develops drugs for respiratory syncytial virus and chronic spontaneous urticaria and offers two protease inhibitor compounds for chronic hepatitis C virus infection.
- Type
- Public
- Status
- Active
- Founded
- 1995
- HQ
- Watertown, MA, US | view all locations
- Website
- https://www.enanta.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Tara L. Kieffer, Chief Product Strategy Officer
Brendan Luu, Chief Business Officer
Matthew Kowalsky, Chief Legal Officer
LocationsView all
1 location detected
Watertown, MA HQ
United States
500 Arsenal Street
Enanta Pharmaceuticals Financials
Summary Financials
- Revenue (Q2, 2026)
- $17.2M
- Net income (Q2, 2026)
- ($13.1M)
- Cash (Q2, 2026)
- $34.9M
- EBIT (Q2, 2026)
- ($11.9M)
- Enterprise value
- $265.3M